Floatz logo

Retifanlimab

Metastatic Neoplasm

BriaCell Therapeutics Corporationmonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

170 Active assets in the Metastatic Neoplasm cohort.

Asset / SponsorPhaseRating
Eloxatin
Ruijin Hospital
Phase 4BBB
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Atezolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2/3BB

View all 50 →

Same molecule, other indications

Retifanlimab is also rated in:

anal canal squamous cell carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →